Trial Profile

A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Rb-Intact Recurrent High-Grade Glioma Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration

Status: Completed

Phase of Trial: Phase 0

Latest Information Update: 03 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Apr 2023 Results assessing Single nuclei RNAseq analysis of recurrent high-grade glioma tumors from patients in the trigger trial of ribociclib plus everolimus presented at the 114th Annual Meeting of the American Association for Cancer Research
11 Jan 2023 Status changed from active, no longer recruiting to completed.
10 Mar 2022 Planned primary completion date changed from 30 Jun 2021 to 30 Jun 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com